Halozyme Therapeutics Enters Exclusive Collaboration with Vertex Pharmaceuticals
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has announced a significant collaboration with Vertex Pharmaceuticals Incorporated. On April 7, the company revealed that its subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Vertex.
Under this agreement, Vertex has obtained a license for Halozyme's Hypercon™ technology. This partnership is expected to enhance Vertex's capabilities in developing innovative therapies, leveraging Halozyme's advanced technology in the biotech sector. The collaboration highlights Halozyme's position in the market and its potential for growth as a key player in the biotechnology industry.
© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
Source: KLEA News